The data are a major positive catalyst for TNGX, validating the PRMT5 + RAS(ON) combination strategy in pancreatic cancer. Traders should watch for: (1) regulatory feedback on Phase 3 design in 2H 2026, (2) upcoming vopimetostat monotherapy data in lung cancer and TNG456 GBM data in 2H 2026, and (3) potential partnership or licensing interest given the strong efficacy signal. The $380M cash runway into 2028 provides financial flexibility to execute on the Phase 3 plan without near-term dilution risk.
Price Chart
Executive Summary
Tango Therapeutics reported highly encouraging initial Phase 1/2 data for vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors (daraxonrasib and zoldonrasib) in MTAP-deleted, RAS-mutant pancreatic cancer. The vopimetostat + daraxonrasib arm showed a 92% objective response rate (ORR) and a 90% six-month progression-free survival (PFS) rate in 12 evaluable second/third-line PDAC patients, with a manageable safety profile. The company plans to rapidly advance this combination into a Phase 3 randomized-controlled trial in front-line pancreatic cancer, subject to regulatory feedback.
Key Facts
- Vopimetostat + daraxonrasib in 2/3L PDAC: 92% ORR (11/12 patients; 9 confirmed), 90% 6-month PFS rate, 100% DCR.
- Vopimetostat + zoldonrasib in 2/3L PDAC: 52% ORR (14/27; 10 confirmed), 74% 6-month PFS rate, 96% DCR.
- Combined ORR across both arms in PDAC: 64% (25/39 patients).
- No discontinuations due to adverse events in either combination arm; no related Grade 4/5 AEs.
- Company intends to initiate a Phase 3 randomized-controlled trial in front-line PDAC in 2H 2026.
- $380M cash and investments as of March 31, 2026; cash runway into 2028.
- Data as of May 28, 2026 cutoff; median follow-up 6.3 months (range 3.3-11.1) for combined PDAC arms.
Financial Impact
Transformative clinical data for vopimetostat in pancreatic cancer, a large unmet need (~40% of PDAC patients are MTAP-deleted). The 92% ORR in 2/3L PDAC with daraxonrasib is unprecedented and supports a potential blockbuster opportunity. No financial figures from the filing to quantify deal value or revenue impact.
Risk Factors
- Early-stage data (n=12 evaluable for daraxonrasib arm) may not replicate in larger, randomized trials.
- Competition from other PRMT5 inhibitors and RAS-targeted therapies in development.
- Regulatory path for accelerated approval is uncertain and subject to FDA feedback.
- Dependence on Revolution Medicines for supply of daraxonrasib and zoldonrasib.
- Clinical trial execution risk for the planned Phase 3 study.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-260679 |
| Document: d158334d8k.htm | 0001193125-26-260679 |
| Document: d158334dex991.htm | 0001193125-26-260679 |
| Document: 0001193125-26-260679-index-headers.html | 0001193125-26-260679 |
| Document: 0001193125-26-260679-index.html | 0001193125-26-260679 |
| Document: 0001193125-26-260679.txt | 0001193125-26-260679 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $25.58 $25.20 | ▲ +1.49% | ▲ +1.04% | $23.20 (+9.28%) |
Aug 11, 2026 7w ago | 8-K | $26.34 $25.44 | ▼ −3.42% | ▼ −3.01% | $23.20 (−11.90%) |
Aug 11, 2026 7w ago | Press Release | $26.34 $25.44 | ▼ −3.42% | ▼ −3.01% | $23.20 (−11.90%) |
Aug 9, 2026 7w ago | Institutional Cluster | $27.67 $25.29 | ▼ −8.60% | ▼ −8.55% | $23.20 (−16.14%) |
Aug 6, 2026 8w ago | 8-K | $27.07 $25.60 | ▼ −5.43% | ▼ −5.83% | $23.20 (−14.28%) |
Jun 11, 2026 16w ago | 144 | $30.94 $27.97 | ▼ −9.60% | ▼ −10.27% | $23.20 (−25.00%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.20 (−22.18%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.20 (−22.18%) |
Jun 10, 2026 16w ago | 424B5 | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.20 (−22.18%) |
Jun 10, 2026 16w ago | 144 | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.20 (−22.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access